

**What effect does regular exercise have on oxidative stress in people with Down syndrome? A  
systematic review with meta-analyses**

Nora Shields,<sup>a,b</sup> Jenny Downs,<sup>c,d</sup> Judy B. de Haan,<sup>e</sup> Nicholas F. Taylor,<sup>a,f</sup> Jennifer Torr,<sup>g</sup> Bo Fernhall,<sup>h</sup>  
Michael Kingsley,<sup>i</sup> George Mnatzaganian,<sup>i</sup> Helen Leonard,<sup>c,j</sup>

<sup>a</sup>School of Allied Health, La Trobe University, VIC 3086, Australia

<sup>b</sup>Northern Health, Epping, VIC 3076, Australia

<sup>c</sup>Telethon Kids Institute, Subiaco, WA 6008, Australia

<sup>d</sup>School of Physiotherapy and Exercise Sciences, Curtin University, Bentley, WA 6102, Australia

<sup>e</sup>BakerIDI Heart and Diabetes Institute, Melbourne, VIC 3004, Australia

<sup>f</sup>Allied Health Clinical Research Office, Eastern Health, Box Hill, VIC 3128, Australia

<sup>g</sup>Department of Psychiatry, School of Clinical Sciences, Faculty of Medicine, Nursing and Health  
Sciences, Monash University, Clayton, VIC 3168, Australia

<sup>h</sup>University of Illinois at Chicago, Chicago, IL 60607, United States

<sup>i</sup>Rural Health School, La Trobe University, Flora Hill, VIC 3550, Australia

<sup>j</sup>University of Western Australia, Crawley, WA 6009, Australia

**Corresponding author:**

Professor Nora Shields

Email: [n.shields@latrobe.edu.au](mailto:n.shields@latrobe.edu.au)

**Authors email addresses:**

Nora Shields                    [n.shields@latrobe.edu.au](mailto:n.shields@latrobe.edu.au)

Jenny Downs                    [Jenny.Downs@telethonkids.org.au](mailto:Jenny.Downs@telethonkids.org.au)

Judy B. de Haan                [Judy.DeHaan@baker.edu.au](mailto:Judy.DeHaan@baker.edu.au)

Nicholas F. Taylor            [n.taylor@latrobe.edu.au](mailto:n.taylor@latrobe.edu.au)

Jennifer Torr            jenny.torr@monash.edu  
Bo Fernhall            fernhall@uic.edu  
Michael Kingsley      M.Kingsley@latrobe.edu.au  
George Mnatzaganian   G.Mnatzaganian@latrobe.edu.au  
Helen Leonard        Helen.Leonard@telethonkids.org.au

**Word count:** 3658

**Abstract count:** 235

**Number of tables:** 2

**Number of figures:** 1

**Abbreviations:** ROS, reactive oxygen species; SOD, superoxide dismutase; GPX, glutathione peroxidase; CAT, catalase; A $\beta$ , amyloid-beta; BMI, body mass index; GSH, reduced glutathione; TBARS= thiobarbituric acid reactive substances; MDA= malondialdehyde; GSSG= oxidised glutathione; LOOH= lipid hydro-peroxide; SMD, standardised mean difference; CI, confidence interval; RCT, randomised controlled trial;



## 28 Introduction

29 Down syndrome (trisomy-21) is the most common known cause of intellectual disability.<sup>1</sup> It has  
30 whole-of-genome and epigenetic effects with consequences for the structure and function of every  
31 organ system. The intellectual disability is usually mild or moderate with variation in ability to  
32 manage daily living activities, and physical impairments include poor cardiovascular fitness.<sup>1</sup>  
33 Improvements in early cardiac care for children with Down syndrome have increased life expectancy<sup>2</sup>  
34 resulting in a growing adult population.<sup>3</sup> However, this population is not ageing well.<sup>4</sup> Half to three  
35 quarters of adolescents and adults with Down syndrome are overweight or obese.<sup>5,6</sup> Older adults with  
36 Down syndrome have high rates of age related morbidity and most experience early cognitive decline  
37 with a cumulative risk of dementia of 45% by 55 years and 80% by 65 years<sup>7</sup> compared to 20 to 35%  
38 by 75 years in the general population.

39

40 Oxidative stress is defined as the imbalance between the generation and removal of reactive oxygen  
41 species (ROS) in the body and is elevated from birth in people with Down syndrome.<sup>8</sup> It is caused by  
42 the overexpression of superoxide dismutase-1 (SOD1), encoded by the SOD1 gene located  
43 on chromosome 21.<sup>8</sup> SOD catalyses the dismutation of the superoxide anion to hydrogen peroxide  
44 which is then converted to water by glutathione peroxidase (GPX) and catalase (CAT). In Down  
45 syndrome, the ratio of SOD to GPX and CAT is increased,<sup>9</sup> producing more hydrogen peroxide than  
46 CAT and GPX can catabolise. The excess hydrogen peroxide and/or its conversion product (hydroxyl  
47 radical), can lead to cellular oxidative damage.<sup>9</sup>

48

49 The consequences of oxidative stress include neurodegeneration and intracellular accumulation of  
50 amyloid-beta (A $\beta$ ) deposits (that define Alzheimer disease),<sup>10</sup> which have a direct role in the cognitive  
51 decline in Down syndrome.<sup>4, 11, 12</sup> The brain is particularly susceptible to oxidative stress because of its  
52 high lipid content. In Down syndrome, increased ROS production renders neurons prone to apoptosis  
53 and more likely to degenerate.<sup>10</sup> Adults with Down syndrome have oxidative damage in the brain  
54 prior to the onset of A $\beta$  deposits.<sup>13</sup> Further, the oxidative system is associated with cognitive

55 functioning in adults with Down syndrome.<sup>14</sup> Increased lipid peroxidation<sup>12</sup> and poorer SOD  
56 functioning predicts poorer memory functioning in older adults with Down syndrome.<sup>15</sup>  
57  
58 Regular exercise reduces oxidative stress and enhances antioxidant activity in the general population<sup>16</sup>  
59 including the elderly.<sup>17, 18</sup> The effects in people with Down syndrome are unclear because their  
60 physiological responses to exercise differ from the general population.<sup>19</sup> The physiological responses  
61 to exercise of people with Down syndrome include diminished cardiac responses, blunted arterial  
62 stiffness responses, autonomic dysfunction and chronotropic incompetence, each contributing to  
63 reduced exercise capacity, limited work performance and poorer exercise economy compared to  
64 healthy controls.<sup>19</sup> Studies also show differences in response to *a single session of aerobic exercise* in  
65 oxidative stress and antioxidant activity<sup>20, 21</sup> between people with and without Down syndrome.  
66 Oxidative stress decreased<sup>21</sup> or did not change<sup>20</sup> in young adults with Down syndrome, whereas in  
67 healthy controls, there was an increase in oxidative stress immediately after exercise followed by a  
68 decrease to resting values after 60 minutes of recovery.<sup>20</sup> There were also between group differences  
69 for antioxidant activity. Immediately after a single exercise session and during recovery total  
70 antioxidant capacity decreased in healthy controls, but did not change in young adults with Down  
71 syndrome.<sup>20</sup>

72

73 Given the different responses to a single session of exercise, we cannot assume people with Down  
74 syndrome will respond in terms of oxidative stress in the same way to regular exercise as the general  
75 population. Therefore, we completed a systematic review and conducted meta-analyses on clinically  
76 homogeneous measures to investigate the effect of regular exercise on oxidative stress in people with  
77 Down syndrome.

78

## 79 **Method**

80 This systematic review was reported with reference to the PRISMA guidelines<sup>22</sup> and was  
81 prospectively registered with PROSPERO (CRD42016048492). Six electronic databases (Medline,  
82 EMBASE, CINAHL, PubMed, AMED, SPORTDiscus) were searched from inception to August

83 2017. The search strategy covered three main concepts: Down syndrome, exercise and oxidative  
84 stress, along with synonyms of each (Supplemental file 1). The search yields were downloaded into  
85 Endnote bibliographic software (version X7) and duplicates were removed. A manual search of the  
86 reference lists of included studies was also performed and citation tracking of the included articles  
87 was completed using Google Scholar.

88

89 Studies were included in the review if (1) the participants had been diagnosed with Down syndrome  
90 (any age), (2) exercise training or physical activity (all types) was completed for at least 6 weeks, (3)  
91 at least one measure of oxidative stress was included, (4) written in English and (5) available in full  
92 text. The exercise or physical activity interventions could include but were not limited to aerobic  
93 training, strength training, walking, swimming or cycling. The setting for the intervention could be at  
94 home, in a laboratory or at a community venue. All quantitative study designs (e.g. pre-test/post-test  
95 intervention designs, controlled trials) that assessed any biomarker measuring outcomes related to the  
96 generation of reactive oxygen species (oxidative stress), its removal and products of reactions  
97 between reactive oxygen species and lipid or protein biomolecules over any time-points were  
98 included.

99

100 Studies were excluded if (1) data from participants with Down syndrome were included as part of a  
101 larger group of participants (e.g. people with intellectual disability) but their data could not be  
102 separated from the larger cohort; (2) the effect of a single session of exercise on oxidative stress was  
103 investigated; (3) they were qualitative studies or narrative reviews. Two reviewers (NS, NT)  
104 independently assessed the titles and abstracts of the search yield for eligible articles based on the  
105 criteria above. Full text versions of articles that could not be excluded based on title and abstract were  
106 obtained and the eligibility criteria reapplied. Reasons for exclusion were recorded. Any discrepancies  
107 were settled by discussion until consensus was reached.

108

109 Data were extracted on the following variables: study design, participant characteristics (age, sex,  
110 BMI, severity of intellectual disability, exercise participation), sample size (number of participants in

111 each study arm), intervention (including mode of exercise, intervention duration, frequency per week,  
112 individual session duration, setting, supervision required, exercise intensity), outcomes measured,  
113 statistical analysis and adverse events. Data were extracted by one reviewer (NS) using a standardised  
114 data extraction form developed for the review and checked by a second reviewer (MK). Any  
115 disagreements were discussed until consensus was reached.

116

117 Risk of bias was assessed independently using the Cochrane Collaboration's Risk of Bias assessment  
118 tool<sup>23</sup> by two reviewers (JD, HL). Seven domains were assessed using this two-part tool: sequence  
119 generation, allocation concealment, blinding of participants and personnel, blinding of outcome  
120 assessment, incomplete outcome data, selective outcome reporting and 'other issues'. The first part of  
121 the tool described what was reported to have happened in the study, in sufficient detail to support a  
122 judgment about the risk of bias. The second part of the tool assigned a judgment relating to the risk of  
123 bias for that domain. The judgment assigned by the reviewers for each domain for each study was  
124 either low risk of bias, high risk of bias, or unclear risk of bias. If insufficient detail was reported of  
125 what happened in the study, the judgment assigned was 'unclear risk' of bias. Disagreements were  
126 resolved through discussion until a consensus was reached.

127

128 Data on participant characteristics and the interventions implemented were synthesised descriptively.

129 Effect sizes were calculated for all studies, where appropriate, using standardised mean differences of  
130 post intervention scores between experimental and control groups,<sup>24</sup> or pre and post intervention  
131 scores for pre-test/post-test studies estimated by<sup>-</sup>, with associated 95% confidence intervals.<sup>25</sup>

132 A random effects meta-analysis, based on DerSimonian and Laird method,<sup>26</sup> was completed for  
133 clinically homogeneous measures. Data were considered clinically homogeneous if the same design  
134 (e.g. pre-test/post-test) was used to evaluate the same or related biomarkers in the same population.

135 Heterogeneity among studies was evaluated by the  $I^2$  statistic, with values below 25% indicating low  
136 heterogeneity, 25-75% moderate heterogeneity, and more than 75% high heterogeneity.<sup>27</sup>

137 Heterogeneity was further investigated by running a meta-regression that investigated the effect of

138 measured covariates (i.e., age, year of study) on the observed heterogeneity in change in biomarker  
139 levels across the studies. Only pre-test/post-test studies in which the effect sizes were possible to  
140 estimate from known *t*-scores were included in the meta-analyses. Assessment of publication bias was  
141 estimated using a funnel plot. Secondary analyses comparing the outcomes of studies that involved  
142 the following comparisons: (1) exercise with usual care or no exercise, and (2) different forms of  
143 exercise (e.g. aerobic versus strength training exercise) were planned, but not conducted due to  
144 insufficient data.

145

## 146 **Results**

147 Electronic database searching and citation tracking identified 159 studies with 99 remaining after the  
148 removal of duplicates (Supplemental file 2). After the application of the eligibility criteria, 11 articles  
149 <sup>28-38</sup> reporting outcomes from seven studies <sup>28, 30, 32, 34, 35, 37, 38</sup> were included in the review (Table 1).  
150 Five articles<sup>29-31, 33,36</sup> reported outcomes from the same set of participants; Ordonez et al <sup>30</sup> was the  
151 first of these to be accepted for publication and so for the purposes of this review was used to  
152 reference this study hereafter. Study designs included one randomised controlled trial,<sup>35</sup> one pre-  
153 test/post-test study with control data for some outcomes,<sup>30</sup> and five single group pre-test/post-test  
154 studies.<sup>28, 32, 34, 37, 38</sup> There was moderate agreement between reviewers when applying eligibility  
155 criteria to titles and abstracts ( $\kappa= 0.68$  95% CI 0.42 to 0.90).

156

157 Seven studies with 144 participants (142 male, 2 female) were included. The weighted mean age of  
158 participants was 18.4 years, ranging from 14.9 to 23.3 years (table 1). The weighted mean BMI was  
159 23.9 kg/m<sup>2</sup> based on data reported in five studies. The severity of intellectual disability was reported  
160 in three studies as mild to moderate,<sup>37</sup> moderate <sup>35</sup> and moderate to severe.<sup>38</sup> Five studies<sup>28,29, 31, 37, 38</sup>  
161 specified that participants were inactive or had not engaged in exercise in the previous six to 12  
162 months. One study<sup>38</sup> reported cardiac status and one study<sup>32</sup> reported on absence of atlanto-axial  
163 instability.

164

[Insert Table 1 about here]

165

166 All studies investigated the effect of aerobic exercise (Table 2). Participants trained on either  
167 treadmills or cycle ergometers in four studies,<sup>28, 30, 34, 38</sup> performed walk/run training on an indoor track  
168 in one study,<sup>37</sup> and completed adapted judo training in one study.<sup>32</sup> One study<sup>35</sup> did not report the type  
169 of training. The average duration of intervention was 12.3 weeks (ranging from 6 to 16), with  
170 participants exercising on average 3 times per week (ranging from 3 to 5 times per week). Exercise  
171 sessions lasted on average 62 minutes (ranging from 40 to 120 minutes including warm up and cool  
172 down phases), with the active phase of training being 34 minutes on average. The exercise intensity  
173 was described in five studies<sup>28, 30, 32, 35, 38</sup> as moderate (i.e. 60-75% peak heart rate or peak oxygen  
174 uptake) and was not reported in the other two studies.<sup>34, 37</sup> Four studies described how training was  
175 progressed. Two studies<sup>28, 35</sup> progressed exercise intensity by increasing training time; one study<sup>34</sup>  
176 increased treadmill speed, incline and time over four weeks, then kept the intensity constant for eight  
177 weeks; and one study<sup>30</sup> increased time and intensity every three weeks for 12 weeks. One study<sup>37</sup>  
178 reported participants trained in groups but did not report group size. The other studies did not report if  
179 participants trained individually or in a group. None of the studies reported who supervised the  
180 training sessions. Only three studies reported where the training was performed: a combination of at  
181 school and in a laboratory;<sup>28</sup> at a university<sup>34</sup> and on an in-door athletic track on a university campus.<sup>37</sup>

182 [Insert Table 2 about here]

183

184 Only one study<sup>32</sup> provided information on intervention fidelity; blood lactate monitoring showed  
185 exercise was performed at moderate intensity below anaerobic threshold. Two studies<sup>29, 38</sup> reporting  
186 using heart rate monitors during training but did not report data from monitoring. Only one study<sup>32</sup>  
187 reported data on attendance, which was above 80%. The same study was the only one to report data  
188 on adverse events and noted no severe mechanical injuries among the participants.<sup>32</sup> Drop-out rates of  
189 participants receiving an exercise intervention were not reported in five studies;<sup>29, 32, 35, 37, 38</sup> there were  
190 no drop outs in one study,<sup>34</sup> but in another study<sup>28</sup> of 11 participants who agreed to participate only six  
191 completed the program.

192

193 A summary of the risk of bias assessment for each study is presented in Supplemental file 3. Six  
194 studies assessed a single group before and after the exercise intervention<sup>28, 30, 32, 34, 37, 38</sup> and therefore  
195 lacked any mechanism to reduce allocation bias. One study assessed two groups for comparison using  
196 randomisation for group allocation but did not describe the process.<sup>35</sup> One study<sup>31</sup> included some  
197 control data for two outcomes but did not use randomisation. Allocation bias was therefore high for  
198 all studies. Researchers and participants were not blinded to procedures in all studies, but the risk of  
199 performance and detection bias was rated as low because blood levels of ROS would be unlikely to be  
200 influenced by this knowledge. Two studies reported high attrition fractions (7/11<sup>28</sup> and 5/15<sup>38</sup>)  
201 suggesting a high risk of attrition bias. The remaining studies did not report dropouts and attrition bias  
202 was rated as unclear. One study<sup>33</sup> did not report data for the control group suggesting a high likelihood  
203 of reporting bias. Reporting bias is not known for the other studies. Sampling bias was likely to be  
204 very high in each of the studies. Sample sizes were small and were unlikely to be representative of the  
205 breadth of phenotype in Down syndrome. For example, only one study recruited females.<sup>28</sup> There was  
206 limited reporting of the category of intellectual disability, comorbidities and levels of physical  
207 activity.

208

209 Biomarkers of oxidative stress measure outcomes related to the generation of ROS (i.e. lipid  
210 peroxidation, protein oxidation) and the removal of ROS (i.e. antioxidant enzymes). Of the studies  
211 included, two<sup>28, 38</sup> measured one biomarker of oxidative stress only; in both studies the biomarker was  
212 an antioxidant (SOD, an antioxidant enzyme and GSH respectively). The other five studies measured  
213 at least two biomarkers, including at least one biomarker measuring outcomes related to the  
214 generation of ROS (e.g. TBARS, MDA, carbonyls) and at least one biomarker measuring the removal  
215 of ROS (e.g. SOD, GPX, CAT, GSH).

216

217 When data were compared across studies, no clear pattern emerged from either descriptive or meta-  
218 analyses for how most individual biomarkers responded to regular exercise in people with Down  
219 syndrome (Supplemental file 4). Different studies showed opposite outcomes for the same  
220 biomarkers. For example, two studies<sup>30, 32</sup> measured protein oxidation via carbonyls. Of these, one

221 study<sup>30</sup> reported a large decrease in carbonyls, while the other<sup>32</sup> reported a moderate increase in  
222 carbonyls after exercise. Statistically insignificant pooled effects sizes, with high levels of  
223 heterogeneity ( $I^2 > 80\%$ ), were observed for four out of the five biomarkers (i.e., TBARS, MDA, SOD,  
224 and GPX) investigated (Figure 1). The exception was catalase which increased significantly after  
225 exercise (SMD 0.39, 95% CI 0.04 to 0.75;  $I^2$  15%). However, the available body of evidence was  
226 characterised by a high risk of bias and a probable publication bias as judged by a visual inspection of  
227 a funnel plot showing asymmetry suggesting a higher probability of publication of studies with either  
228 a negative or positive significant outcome (Supplemental file 5). Random effects meta-regression  
229 showed that age significantly accounted for just over one third (36%) of the observed heterogeneity  
230 (Adjusted  $R^2 = 0.361$ ,  $p = 0.008$ ).

231 [Insert Figure 1 about here]

232

233 Given there was no clear pattern in how biomarkers of oxidative stress in people with Down  
234 syndrome responded to exercise, the biomarkers measured in the five studies that included more than  
235 one outcome were also interpreted relative to each other. Two studies<sup>30, 34</sup> reported a decrease in one  
236 biomarker measuring outcomes related to the generation of ROS and an increase in one biomarker  
237 measuring antioxidant activity after regular exercise (Supplemental file 4). However, the other three  
238 studies<sup>32, 35, 37</sup> (including one small RCT) reported an increase in biomarkers measuring outcomes  
239 related to the generation of ROS (TBARS, MDA, carbonyls, LOOH) in people with Down syndrome  
240 after exercise. In these three studies, the associated change in the antioxidant system varied. For  
241 example, Monteiro et al<sup>35</sup> reported a decrease in GSSG, an increase in GSH and no change in SOD  
242 which suggested some adaptation to exercise as GSSG was converted to GSH with no associated  
243 change in antioxidant enzymes. Aguiar et al<sup>32</sup> reported a concurrent increase in the antioxidant  
244 enzymes SOD and CAT but no change in GPX, again suggesting some adaptation to exercise  
245 occurred. Lastly, data reported by Ozbey et al<sup>37</sup> suggested a decrease in both SOD and GPX and no  
246 change in CAT.

247

248

## 249 **Discussion**

250 The main finding of this review was that no clear pattern emerged for how individual biomarkers of  
251 oxidative stress or antioxidant activity responded to regular short term aerobic exercise programs in  
252 people with Down syndrome. People with Down syndrome generally participate in low levels of  
253 physical activity and exercise<sup>39, 40</sup> but those who experience less cognitive decline have lower  
254 oxidative stress,<sup>12</sup> and may have engaged in more physical activity. These uncertainties need to be  
255 resolved in order to understand more comprehensively the biological and functional benefits of  
256 regular exercise to people with Down syndrome.

257

258 The high risk of bias of the included studies in this review provides an explanation for the uncertain  
259 findings. All included studies, with one exception, used single group pre-test/post-test designs which  
260 are subject to bias and can overestimate the size of any effect.<sup>41</sup> Available control data were minimal  
261 and also of high risk of bias; the included randomised controlled trial did not use concealed allocation  
262 or blinded assessment and the only other available control data (7 participants) presumably were  
263 collected after completion of the pre-test/ post-test trial.<sup>35</sup> In addition, the choice of biomarkers to  
264 measure oxidative stress and antioxidant activity may have been a source of error and obscured any  
265 true effects of exercise for people with Down syndrome. For example, TBARS and MDA are now  
266 considered less accurate markers of oxidative stress<sup>42</sup> and newer, more specific probes to measure  
267 outcomes related to ROS production such as L012 (superoxide),<sup>43</sup> DCFDA (hydrogen peroxide),<sup>44</sup>  
268 urinary isoprostanes<sup>45</sup> and oxidised DNA bases<sup>46</sup> provide better indications of ROS levels.<sup>47</sup> Also,  
269 some included studies only measured a single biomarker,<sup>28, 38</sup> which makes the data difficult to  
270 interpret. For example, an increase in SOD could be positive if associated with a concurrent increase  
271 in GPX and CAT. This makes it difficult to interpret the meta-analysis of a single biomarker, CAT,  
272 which reached statistical significance. The high risk of bias in study designs plus limitations in the  
273 choice of biomarkers may explain the variation in reported results.

274

275 Sample sizes were small (ranging from 4 to 38 participants) and resulted in large confidence intervals  
276 around the estimate of effect. For example, the estimates of effect for the antioxidant activity of SOD  
277 in the controlled study ranged from -0.91 to 1.05, that is, with 95% confidence there could possibly  
278 have been a large effect that SOD was either reduced or increased in response to regular exercise.<sup>35</sup>  
279 The studies were also not representative of the breadth of phenotype in Down syndrome. Only one  
280 included study recruited females<sup>28</sup> and only two included studies reported co-morbidities.<sup>32, 38</sup> These  
281 sampling biases limit the generalisability of findings.

282

283 There is a need to resolve the issue of whether regular exercise has a positive or negative effect on  
284 oxidative stress for people with Down syndrome across the breadth of the phenotype. This will enable  
285 development of strategies to improve the health of people with Down syndrome, specifically to  
286 address the consequences of excessive oxidative stress such as accelerated ageing, neurodegeneration,  
287 impaired cognitive functioning and dementia.<sup>10, 13, 48</sup> If regular exercise has a positive effect on  
288 oxidative stress, it would strengthen the rationale to support efforts to promote physical activity,  
289 including regular (structured) exercise, in people with Down syndrome. In this case efforts would  
290 focus on strategies to increase exercise opportunities and promote exercise adherence.<sup>49-51</sup> However, if  
291 in fact, regular exercise has a negative effect on oxidative stress for people with Down syndrome, then  
292 exercise programs for people with Down syndrome may need to be tailored so that the known benefits  
293 of exercise in this group (improved strength, cardiovascular fitness, and social inclusion)<sup>52-54</sup> are  
294 retained without causing biological harm. There is strong evidence from a meta-analysis of 19  
295 controlled trials that regular exercise decreases biomarkers of oxidative stress and increases anti-  
296 oxidant activity in people in the general population.<sup>55</sup> Similar evidence from adequately powered  
297 randomised controlled trials are required to resolve this question in Down syndrome and thereby  
298 inform recommendations regarding the type and dose of exercise that is most likely to be of biological  
299 beneficial to people with this condition.

300

301 The main strength of this systematic review was the rigorous methods used, which included  
302 prospective registration, detailed search strategies, evaluation of the risk of bias, meta-analyses and

303 reporting consistent with the PRISMA guidelines.<sup>22</sup> Available data are however limited and of a poor  
304 quality. However, the included studies provide preliminary data to highlight the importance of  
305 clarifying the effects on oxidative stress in people with Down syndrome, and whether regular exercise  
306 can ameliorate the effects of the secondary health conditions to which people with Down syndrome  
307 are vulnerable. Also, since the included studies in the meta-analyses followed a pre and post study  
308 design or a pre-experimental design without controls, they had little power to establish causality.

309

### 310 **Conclusions**

311 Our systematic review suggests there remains uncertainty about the effect of regular exercise on  
312 oxidative stress and antioxidant activity in people with Down syndrome. Since oxidative stress  
313 predates clinical pathology in people with Down syndrome, there is a need to resolve this uncertainty  
314 with adequately powered randomised controlled trials.

315

### 316 **Practical implications**

- 317 • Available studies on the effect of regular exercise on oxidative stress in people with Down  
318 syndrome are at high risk of bias.
- 319 • No clear pattern emerged for how most individual biomarkers of oxidative stress or  
320 antioxidant activity responded to short term aerobic exercise programs in people with Down  
321 syndrome.
- 322 • Data from pre-test/post-test studies showed catalase increases significantly after exercise in  
323 people with Down syndrome.

324

### 325 **Acknowledgements**

326 The authors have no conflicts of interest to declare. No financial assistance for this project was  
327 received.

## 328 References

- 329 1. Roizen N, Patterson D. Down's syndrome. *Lancet* 2003; 361:1281-1289
- 330 2. Glasson EJ, Jacques A, Wong K, et al. Improved survival in Down syndrome over the last 60  
331 years and the impact of perinatal factors in recent decades. *J Pediatr* 2016; 169:214-220.
- 332 3. Sinai A, Bohnen I, Strydom A. Older adults with intellectual disability. *Curr Opin Psych* 2012  
333 25:359-364.
- 334 4. Torr J, Strydom A, Patti P, et al. Aging in Down syndrome: morbidity and mortality. *J Policy*  
335 *Prac Intellect Disabil* 2010; 7:70-81.
- 336 5. Pikora T, Bourke J, Bathgate K, et al. Health conditions and their impact among adolescents and  
337 young adults with Down syndrome. *PloS One* 2014; 9:e96868.
- 338 6. Stancliffe R, Lakin K, Larson S, et al. Overweight and obesity among adults with intellectual  
339 disabilities who use services in 20 us states. *Am J Intellect Dev Disabil* 2011; 116:401-418.
- 340 7. McCarron M, McCallion P, Reilly E, et al. A prospective 14-year longitudinal follow-up of  
341 dementia in persons with Down syndrome. *J Intellect Disabil Res* 2014; 58:61-70.
- 342 8. Jovanovic SV, Clements D, MacLeod K. Biomarkers of oxidative stress are significantly  
343 elevated in Down syndrome. *Free Radic Biol Med* 1998; 25:1044-1048.
- 344 9. de Haan JB, Cristiano F, Iannello R, et al. Elevation in the ratio of cu/zn-superoxide dismutase to  
345 glutathione peroxidase activity induces features of cellular senescence and this effect is mediated  
346 by hydrogen peroxide. *Hum Mol Genet* 1996; 5:283-292.
- 347 10. Busciglio J, Yankner B. Apoptosis and increased generation of reactive oxygen species in Down  
348 syndrome. *Nature* 1995; 378:776-779.
- 349 11. Perluigi M, Butterfield DA. Oxidative stress and Down syndrome: a route toward alzheimer-like  
350 dementia. *Curr Gerontol Geriatr Res* 2012; Article ID 724904, doi:10.1155/2012/724904.
- 351 12. Zis P, McHugh P, McQuillin A, et al. Memory decline in Down syndrome and its relationship to  
352 ipf2alpha, a urinary marker of oxidative stress. *PloS One* 2014; 9:e97709.
- 353 13. Nunomura A, Perry G, Pappolla MA, et al. Neuronal oxidative stress precedes amyloid- $\beta$   
354 deposition in Down syndrome. *J Neuropath Exp Neuro* 2000; 59:1011-1017.

- 355 14. Strydom A, Dickinson MJ, Shende S, et al. Oxidative stress and cognitive ability in adults with  
356 Down syndrome. *Prog Neuro-Psychopharmacol Biol Psychiatry* 2009; 33:76-80.
- 357 15. Zis P, Dickinson M, Shende S, et al. Oxidative stress and memory decline in adults with Down  
358 syndrome: longitudinal study. *J Alzheimers Dis* 2012; 31:277-283.
- 359 16. Elosua R, Molina L, Fito M. Response of oxidative stress biomarkers to a 16-week aerobic  
360 physical activity program and to acute physical activity in healthy young men and women.  
361 *Atherosclerosis* 2003; 167:326-334.
- 362 17. Fatouros IG, Jamurtas AZ, Villiotou V, et al. Oxidative stress responses in older men during  
363 endurance training and detraining. *Med Sci Sport Exer* 2004; 36:2065-2072.
- 364 18. Rosado-Pérez J, Santiago-Osorio E, Ortiz R, et al. Tai chi diminishes oxidative stress in Mexican  
365 older adults. *J Nutri Health Aging* 2012; 16:642-646.
- 366 19. Mendonca G, Pereira F, Fernhall B. Reduced exercise capacity in persons with Down syndrome:  
367 cause, effect, and management. *Ther Clin Risk Manag* 2010; 6:601-610.
- 368 20. Flore P, Bricout V-A, Van Biesen D, et al. Oxidative stress and metabolism at rest and during  
369 exercise in persons with Down syndrome. *Eur J Cardiovasc Prev Rehabil* 2008; 15:35-42.
- 370 21. Zambrano JC, Marquina R, Sulbarán N, et al. Aerobic exercise reduced oxidative stress in saliva  
371 of persons with Down syndrome. *Res Sport Med* 2009; 17:195-203.
- 372 22. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-  
373 analyses: the PRISMA statement. *Ann Int Med* 2009; 151:264-269.
- 374 23. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies, Chapter 8, in:  
375 *Cochrane handbook for systematic reviews of interventions version 5.1.0* Higgins JPT Green S  
376 editors. Available from <http://handbook.cochrane.org>, The Cochrane Collaboration, 2011.  
377 Accessed 13<sup>th</sup> March 2017.
- 378 24. Deeks JJ, Higgins JPT, Altman DG H. Analysing data and undertaking meta-analyses, Chapter 9,  
379 in: *Cochrane handbook for systematic reviews of interventions version 5.1.0* Higgins JPT Green  
380 S editors. Available from <http://handbook.cochrane.org>: The Cochrane Collaboration, 2011.  
381 Accessed 13<sup>th</sup> March 2017.

- 382 25. Rosenthal R. *Meta-analytic procedures for social research*. Newbury Park, CA: SAGE  
383 Publications Inc, 1991.
- 384 26. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7:177-188.
- 385 27. Higgins J, Thompson S, Deeks J, et al. Measuring inconsistency in meta-analysis. *BMJ* 2003;  
386 327:557-560.
- 387 28. Eberhard Y, Etteradossi J, Debu B. Biological changes induced by physical activity in  
388 individuals with Down's syndrome. *Adapt Phys Act Quarter* 1997; 14:166-175.
- 389 29. Ordonez FJ, Manuel R, Manuel RR. Regular physical activity increases glutathione peroxidase  
390 activity in adolescents with Down syndrome. *Clin J Sport Med* 2006; 16:355-356.
- 391 30. Ordonez FJ, Rosety M, Rosety-Rodriguez M. Regular exercise did not modify significantly  
392 superoxide dismutase activity in adolescents with Down's syndrome. *Br J Sport Med* 2006;  
393 40:717-718.
- 394 31. Javier Ordonez F, Rosety-Rodriguez M. Regular exercise attenuated lipid peroxidation in  
395 adolescents with Down's syndrome. *Clin Biochem* 2007; 40:141-142.
- 396 32. Aguiar AS, Jr., Tuon T, Albuquerque MM, et al. The exercise redox paradigm in the Down's  
397 syndrome: Improvements in motor function and increases in blood oxidative status in young  
398 adults. *J Neural Transm* 2008; 115:1643-1650.
- 399 33. Rosety-Rodriguez M, Rosety I, Fornieles-Gonzalez G, et al. A 12-week aerobic training  
400 programme reduced plasmatic allantoin in adolescents with Down syndrome. *Br J Sport Med*  
401 2010; 44:685-687.
- 402 34. Meguid NA, Eltohamy AM, Anwar M, et al. Efficacy of selected treadmill training programme  
403 on oxidative stress in adolescents with Down syndrome. *East Med Health J* 2013; 19:S131-S137.
- 404 35. Monteiro CP, Varela A, Pinto M, et al. Effect of an aerobic training on magnesium, trace  
405 elements and antioxidant systems in a Down syndrome population. *Magnes Res* 1997; 10:65-71.
- 406 36. Ordonez FJ, Rosety I, Rosety MA, et al. Aerobic training at moderate intensity reduced protein  
407 oxidation in adolescents with Down syndrome. *Scand J Med Sci Sports* 2012; 22:91-94.

- 408 37. Ozbey U, Arslan C, Savucu Y, et al. Oxidative stress and altered levels of antioxidants in  
409 adolescents with down syndrome during pre-exercise and post-exercise. *African J Microbiol Res*  
410 2012; 6:5625-5630.
- 411 38. Aleksander-Szymanowicz P, Marchewka A, Dabrowski Z, et al. The influence of moderate-  
412 intensity physical effort on peripheral blood in adults with Down syndrome - a pilot study. *J*  
413 *Physiol Pharmacol* 2014; 65:733-738.
- 414 39. Esposito PE, MacDonald M, Hornyak JE, et al. Physical activity patterns of youth with Down  
415 syndrome. *Intellect Dev Disabil* 2012; 50:109-119.
- 416 40. Phillips AC, Holland AJ. Assessment of objectively measured physical activity levels in  
417 individuals with intellectual disabilities with and without Down's syndrome. *PLoS One* 2011;  
418 6:e28618.
- 419 41. Bland JM, Altman DG. Comparisons against baseline within randomised groups are often used  
420 and can be highly misleading. *Trials* 2011; 12:264.
- 421 42. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid  
422 peroxidation and peroxidative tissue injury. *Free Radical Biol Med* 1990; 9:515-540.
- 423 43. Daiber A, August M, Baldus S, et al. Measurement of nad (p) h oxidase-derived superoxide with  
424 the luminol analogue l-012. *Free Radical Biol Med* 2004; 36:101-111.
- 425 44. Eruslanov E, Kusmartsev S. Review of cellular ros generation and antioxidant defense  
426 mechanisms and methods for their analysis using h2dcfda. *Meth Mol Biol* 2010; 594:57-72.
- 427 45. Milatovic D, Montine TJ, Aschner M. Measurement of isoprostanes as markers of oxidative  
428 stress. *In Vitro Neurotoxicol: Method Protocol* 2011:195-204.
- 429 46. Pryor WA. Measurement of oxidative stress status in humans. *Cancer Epidemiol Biomark Prev*  
430 1993; 2:289-292.
- 431 47. Stephens JW, Khanolkar MP, Bain SC. The biological relevance and measurement of plasma  
432 markers of oxidative stress in diabetes and cardiovascular disease. *Atherosclerosis* 2009;  
433 202:321-329.
- 434 48. Ballard C, Mobley W, Hardy J, et al. Dementia in Down's syndrome. *Lancet Neurol* 2016;  
435 15:622-636.

- 436 49. Rimmer J, Rowland J. Health promotion for people with disabilities. 2008;2:409-20. *Am J*  
437 *Lifestyle Med* 2008; 2:409-420.
- 438 50. Shields N, Taylor N. The feasibility of a physical activity programme for young adults with  
439 Down syndrome: A phase II randomised controlled trial. *J Intellect Dev Disabil* 2015; 40:115-  
440 125.
- 441 51. Mahy J, Shields N, Taylor N, et al. Barrier & facilitators to physical activity in adults with Down  
442 syndrome. *J Intellect Disabil Res* 2010; 54:795–805.
- 443 52. Shields N, Taylor NF, Wee E, et al. A community-based strength training programme increases  
444 muscle strength and physical activity in young people with Down syndrome: a randomised  
445 controlled trial. *Res Dev Disabil* 2013; 34:4385-4394.
- 446 53. Dodd KJ, Shields N. A systematic review of the outcomes of cardiovascular exercise programs  
447 for people with Down syndrome. *Arch Phys Med Rehab* 2005; 86:2051-2058.
- 448 54. Li C, Chen S, How YM, et al. Benefits of physical exercise intervention on fitness of individuals  
449 with Down syndrome: a systematic review of randomized-controlled trials. *Int J Rehabil Res*  
450 2013; 36:187-195.
- 451 55. de Sousa CV, Sales MM, Rosa TS, et al. The antioxidant effect of exercise: a systematic review  
452 and meta-analysis. *Sport Med* 2017; 47: 277–293.
- 453

454 **Figure legend**

455 **Figure 1** Meta-analysis of data from pre-test/post-test studies using biomarkers of oxidative  
456 stress (A), CAT (B), GPX (C), SOD (D).

**Table 1:** Characteristics of the included studies

Study	Research design	Sample size	Age (yrs)	Sex	BMI (kg/m <sup>2</sup> )	Severity of intellectual disability	Previous exercise participation	Oxidative stress biomarkers	Antioxidant biomarkers	Adverse events
Aguiar et al [32]	Single group pre-test/ post-test	21	23.3±2.1	21M	23.0±1.2	Not reported	Not reported	TBARS (E&S) lipid hydroperoxides (S) carbonyl (E&S)	SOD (E&S) CAT (E&S) GPX (S)	No severe mechanical injuries
Aleksander-Szymanowicz et al [38]	Single group pre-test/ post-test	15	22.4±0.9	15M	27.5 (no SD reported)	Moderate or severe	“Non-trained”		GSH (E)	Not reported
Eberhard et al [28]	Single group pre-test/ post-test	4	18.4±1.8	2M, 2F	Not reported	Not reported	Inactive; 1hr physical education class per week		SOD (E)	Not reported
Meguid et al [34]	Single group pre-test/ post-test	30	16.6±1.1	30M	27.7±1.9	Not reported	Not reported	MDA (pl)	GPX (E)	Not reported
Monteiro et al [35]	RCT	16 (8 per group)	21.3±2.8	16M	Not reported	Moderate (IQ 39±9.7)	Not reported	TBARS (pl) GSSG (E & pl)	GSH (E & pl) SOD (E)	Not reported
Ozbey et al [37]	Single group pre-test/ post-test	20	14.9±7.1	20M	31.9±6.8	IQ 40-60	None for previous 12 months	MDA (pl) β-carotene (pl) Vit A (pl)	SOD (E) GPX (E) CAT (E)	Not reported
Ordonez et al [30] Ordonez et al [29] Rosety-Rodriguez et al [33] Ordonez et al [31] Ordonez et al [36]	Single group pre-test/ post-test with control data for 2 biomakers*	31 (+7 control for 2 outcomes)	16.3±1.1	31M	29.3±1.3	Not reported	None in previous 6 months	Carbonyl (pl)* MDA (pl)* uric acid (pl) allantoin (pl)	GPX(E) SOD(E)	Not reported

Note: \*This study included control data from 7 males participants for two biomarkers only (carbonyl and MDA). These 5 papers all report outcomes from the same study. Two papers provide data from a n=7 control group. E=erythrocyte; Pl= plasma; S= serum; RCT= randomised controlled trial; yrs= years; BMI= body mass index; M= male; F= female; SD= standard deviation; Ex= exercise





**Table 2:** Overview of the intervention protocols

Study	Exercise type	Intervention (exercise mode)	Length of program (weeks)	Frequency (per week)	Intensity	Duration (of each session in minutes)	Progression	Individual or Group	Supervision (ratio and training of supervisor)	Location (e.g. clinic, gym, laboratory)	Materials used (e.g. heart rate monitors)	Adherence (intervention intensity fidelity)	Attendance (number of sessions attended)
Aguiar et al [32]	Aerobic	Adapted judo training	16	3	Moderate (monitored by lactate threshold)	50	Not reported	Not reported	Not reported	Not reported	Blood lactate monitoring	Blood lactate levels show exercise performed below anaerobic threshold	Above 80%
Aleksander-Szymanowicz et al [38]	Aerobic	Cycle ergometer	6	3	Moderate 60-75% peak heart rate	10 minute warm up, 20-25 minute main phase, 10 minute cool down	Not reported	Not reported	Not reported	Not reported	Heart rate monitor	Not reported	Not reported
Eberhard et al [28]	Aerobic	Activities (games with walking & running x 1hr) + cycle ergometer (twice a week)	12	School activities daily, cycle ergometer 2	Moderate (60% $\dot{V}O_2$ max)	“up to 2 hours”	↑ time until participants could do continuous exercise for 60 mins	Not reported	Not reported	School and laboratory	Not reported for training	Not reported	Not reported
Meguid et al [34]	Aerobic	Treadmill	12	3	Not reported	10-40 (included warm-up, active training, cool down phases)	Time speed and incline increased gradually over 4 weeks, then constant for 8 weeks	Not reported	Not reported	University	Not reported	Not reported	Not reported

Monteiro et al [35]	Aerobic	Not reported	16	3	Moderate (60-75% VO <sub>2</sub> peak)	10 mins warm up, 15-25 mins active training, 5 mins cool down	Increase session 5 mins every 5 weeks	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported
Ozbey et al [37]	Aerobic	Run/walk	12	3	Not reported	10-15 mins warm up, 30 minute run/walk, 10-15 mins cool down	Not reported	Group (number not reported)	Not reported	In-door athletic track on university campus	Not reported	Not reported	Not reported
Ordonez et al [29-31, 36] Rosety-Rodriguez et al [33]	Aerobic	Treadmill	12	3	Moderate (60-75% peak HR)	10-15 mins warm-up, 20-35 minute active training part, 10 min cool down	Increase duration of active training by 5 min every 3 weeks; increased intensity by 5% every 3 weeks	Not reported	'Supervised by researchers'	Not reported	Heart rate monitor	Not reported	Not reported


---

**Figure**  
[Click here to download high resolution image](#)



**Supplemental file 1: Search strategy**

1. Down Syndrome/
2. Intellectual Disability/
3. Down syndrome.ti,ab.
4. intellectual disability.ti, ab.
5. Trisomy 21.ti, ab.
6. mental retardation.ti,ab.
7. intellectual impairment.ti,ab.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. Exercise/ or Exercise Therapy/
10. Motor Activity/
11. exercise.ti,ab.
12. physical activity.ti,ab.
13. exercise therap\$.ti,ab.
14. physical exercise.ti,ab.
15. physical training.ti,ab.
16. aerobic training.ti,ab.
17. aerobic exercise.ti,ab.
18. physical fitness.ti,ab.
19. progressive resistance training.ti,ab.
20. strength training.ti,ab.
21. weight training.ti,ab.
22. anaerobic exercise.ti,ab.
23. therapeutic exercise.ti,ab.
24. resistance training.ti,ab.
25. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26. Oxidative Stress/
27. Reactive Oxygen Species/
28. oxidative stress.ti,ab.
29. reactive oxygen species.ti,ab.
30. oxidative damage.ti,ab.
31. Antioxidant defense.ti,ab.
32. malondialdehyde.ti,ab.
33. pro-oxidant\$.ti,ab.
34. superoxide dismutase.ti,ab.
35. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
36. 8 and 25 and 35



**Supplemental file 2:** PRISMA flowchart for study selection

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Aguiar 2008	-	-	+	?	?	+
Aleksander-szymanowicz 2014	-	-	+	?	-	+
Eberhard 1997	-	-	+	?	-	+
Meguid 2013	-	-	+	?	?	+
Monteiro 1997	?	?	+	?	?	+
Ordonez 2006	-	-	+	?	?	-
Ozbey 2012	-	-	+	?	?	+

**Supplemental file 3:** Summary of the risk of bias assessment

**Supplemental file 4:** Biomarkers of oxidative stress and anti-oxidant enzymes and their response to regular exercise in people with Down syndrome

<b>Biomarker</b>	<b>Sample type</b>	<b>Study</b>	<b>Sample size</b>	<b>Result</b>	<b>Effect size (95% CI)</b>
<i>Antioxidant</i>					
SOD	Erythrocyte	Monteiro et al [35]*	16	No change in SOD	0.07 (-0.91 to 1.05)
	Erythrocyte	Aguiar et al [32]	21	↑ SOD	0.62 (0.16 to 1.07)
	Erythrocyte	Ozbey et al [37]	20	↓ SOD	-0.71 (-1.18 to -0.24)
	Erythrocyte	Ordonez et al [30]	31	No change in SOD	0.30 (-0.05 to 0.67)
	Erythrocyte	Eberhard et al [28]	4	No change in SOD	NA
	Serum	Aguiar et al [32]	21	No change in SOD	0.12 (-0.32 to 0.58)
GPX	Erythrocyte	Meguid et al [34]	30	↑ GPX	0.41 (0.04 to 0.79)
	Erythrocyte	Ozbey et al [37]	20	↓ GPX†	-0.52 (-0.99 to 0.05)
	Erythrocyte	Ordonez et al [29]	31	↑ GPX	0.48 (0.11 to 0.85)
	Serum	Aguiar et al [32]	21	No change in GPX	0.12 (-0.33 to 0.57)
CAT	Erythrocyte	Ozbey et al [37]	20	No change in CAT	0.21 (-0.25 to 0.68)
	Erythrocyte	Aguiar et al [32]	21	↑ CAT	0.57 (0.12 to 1.03)
	Serum	Aguiar et al [32]	21	↑ CAT†	0.34 (-0.11 to 0.79)
GSH	Plasma	Monteiro et al [35]*	16	↑ GSH	1.85 (0.68 to 3.02)
	Erythrocyte	Monteiro et al [35]*	16	No change in GSH	-0.74 (-1.76 to 0.27)
	Erythrocyte	Aleksander-Szymanowicz et al [38]	15	↑ GSH	1.07 (0.51 to 1.62)
<i>Lipid peroxidation</i>					
TBARS	Plasma	Monteiro et al [35]*	16	↑ TBARS†	0.93 (-0.1 to 1.96)
	Plasma	Aguiar et al [32]	21	No change in TBARS	0.10 (-0.35 to 0.55)
	Erythrocyte	Aguiar et al [32]	21	↑ TBARS	0.59 (0.13 to 1.04)
MDA	Plasma	Ordonez et al [31]	31	↓ MDA	-0.48 (-0.85 to -0.11)
		Meguid et al [34]	30	↓ MDA	-0.74 (-1.12 to -0.37)
		Ozbey et al [37]	20	↑ MDA	0.66 (0.20 to 1.13)

<i>Protein oxidation</i>					
Carbonyl	Plasma	Ordonez et al [31, 36]*	38	↓ carbonyls	-7.93 (-9.89 to -5.97)
	Plasma	Aguiar et al [32]	21	↑ carbonyls	0.62 (0.16 to 1.07)
	Erythrocyte	Aguiar et al [32]	21	↑ carbonyls	0.58 (0.12 to 1.03)
<i>Other outcomes</i>					
LOOH	Plasma	Aguiar et al [32]	21	↑ LOOH	0.49 (0.04 to 0.95)
GSSG	Plasma	Monteiro et al [35]*	16	No change in GSSG	0.8 (-0.22 to 1.82)
	Erythrocyte	Monteiro et al [35]*	16	↓ GSSG	-4.32 (-6.11 to -2.53)
Uric acid	Plasma	Rosety-Rodriguez et al [33]	31	No change in uric acid	0.29 (-0.07 to 0.66)
Allantoin	Plasma	Rosety-Rodriguez et al [33]	31	↓ allantoin	-0.66 (-1.02 to -0.29)

NA= data unavailable to calculate an effect size; CI= confidence interval

SOD=superoxide dismutase; GPX= glutathione peroxidase; CAT= catalase; GSH= reduced glutathione; TBARS= thiobarbituric acid reactive substances; MDA= malondialdehyde; GSSG= oxidised glutathione; LOOH= lipid hydro-peroxide

\* controlled study

† a significant change post intervention was reported in the original paper.

## **Acknowledgements**

The authors have no conflicts of interest to declare. No financial assistance for this project was received.